πReal-world implications of #SELECT trial.
31% of patients with #MI are SELECT-eligible to treatment with semaglutide.
Number needed to treat of 49 patients to prevent one MACE.
shorturl.at/movAK
#Obesity #Cardiotwitter @JACCJournals @AUHdk @AarhusUni @MaleneKHansen
31% of patients with #MI are SELECT-eligible to treatment with semaglutide.
Number needed to treat of 49 patients to prevent one MACE.
shorturl.at/movAK
#Obesity #Cardiotwitter @JACCJournals @AUHdk @AarhusUni @MaleneKHansen